What is the difference between 1mg and 2.4mg weekly semaglutide doses in research?

The 1mg weekly dose was primarily studied in the SUSTAIN programme for glycaemic control. The 2.4mg dose studied in STEP trials was optimised for weight management and showed greater average weight reduction of approximately 14.9% versus body weight at baseline.

How does semaglutide compare to older GLP-1 agonists like liraglutide?

Semaglutide has a significantly longer half-life (7 days vs. 13 hours for liraglutide), allowing once-weekly dosing. Phase 3 data indicate semaglutide produces greater weight reduction than liraglutide at approved doses.

Bestseller

Semaglutide

Name: Semaglutide
Price: 35 USD
Availability: InStock

Long-acting GLP-1 receptor agonist. STEP-1 trial reported 14.9% average body weight reduction at 2.4mg weekly dose over 68 weeks.

Fat LossGH Boost

● In Stock

Select Variant

Quantity (vials)

Buy more, save more

—

1+ vials

−5%

3+ vials

−10%

5+ vials

−20%

10+ vials

Total Price

$35

For research & laboratory use only. Not for human consumption.

Half-Life

7 days

Administration Route

Subcutaneous injection

14.9% Weight Reduction

Clinically validated in 68-week STEP-1 Phase 3 trial

Cardiovascular Benefit

Reduced MACE risk in the SUSTAIN-6 outcomes trial

Blood Sugar Control

GLP-1R agonism drives glucose-dependent insulin release

Effect Profile

Based on primary research mechanisms

Fat Loss

Hunger Control

Metabolic Health

Energy

Effect Timeline

Start

Hunger signals blunted; food cravings significantly reduced

Week 4

2–4% body weight reduction; nausea subsides

Week 8

Consistent fat loss; HbA1c begins declining

Week 16

6–10% weight loss; cardiovascular markers improve

Start — Week 1–2

Hunger signals blunted; food cravings significantly reduced

Week 4

2–4% body weight reduction; nausea subsides

Week 8

Consistent fat loss; HbA1c begins declining

Week 16

6–10% weight loss; cardiovascular markers improve

Mechanism of Action

Semaglutide is a modified GLP-1 analog with a C18 fatty acid chain attached via a linker to lysine at position 34. The modification enables albumin binding that extends plasma half-life to approximately seven days. It activates GLP-1 receptors in the pancreas, hypothalamus, and gut to reduce glucagon secretion, slow gastric emptying, stimulate glucose-dependent insulin release, and suppress appetite through central satiety pathways.

Scientific Research

Once-weekly semaglutide in adults with overweight or obesity (STEP-1)

New England Journal of Medicine (2021)

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6)

New England Journal of Medicine (2016)

Product FAQs

Stacks Well With

Cagrilintide

Long-acting amylin receptor agonist with a 7-day half-life. Studied for weight management both as monotherapy and in combination with semaglutide (CagriSema).